Hongming Chen
陈红敏
Hongming Chen is a scientist-entrepreneur who co-founded and leads METiS Pharmaceuticals, a Hong Kong-listed company applying AI to drug delivery. Per a 2022 5Y Capital piece, she holds membership in the US National Academy of Engineering (described as "院士") and helped pioneer AI-driven drug delivery alongside MIT-trained scientists including Caida Lai and Wenshou Wang . Monolith Capital, in a 2025 profile of Lai, identified Chen as Lai's partner at the firm . Heart Capital noted in May 2026 that she had taken METiS public on the Hong Kong Stock Exchange, with the firm praising her integration of medicinal chemistry expertise into an AI platform .
elsewhere's corpus does not cover Chen's background in depth beyond her METiS role.
AI-generated — may contain errors, please verify.
Coverage
Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange IPO — FreeS Fund invested in four consecutive early rounds.
From Whiteboard Equations to the "SpaceX" of Pharma
Heart Capital Congratulates METiS Pharmaceuticals on Successful Listing on the Main Board of the Hong Kong Stock Exchange | Heart Star PORTFOLIO
The world's first publicly listed AI drug delivery company.
The SpaceX of Pharma: Caida Lai's Nanorocket
Only those with fire in their eyes can build rockets.
5Y News | 5Y Capital Portfolio Company METiS Pharmaceuticals Closes $100 Million Series C Round
Focused on "AI-powered drug delivery."
5Y News | METiS Pharmaceuticals Closes Two Consecutive Rounds Raising $150 Million Total
Become an industry innovation leader.
